Q0221 Insurance Policy Changes

HCPCS Q0221 is officially defined as "Injection, tixagevimab and cilgavimab, for the pre-exposure prophylaxis only, for certain adults and pediatric individuals (12 years of age and older weighing at least 40kg) with no known sars-cov-2 exposure, who either have moderate to severely compromised immune systems or for whom vaccination with any available covid-19 vaccine is not recommended due to a history of severe adverse reaction to a covid-19 vaccine(s) and/or covid-19 vaccine component(s), 600 mg." HCPCS Q0221 is referenced in 3 tracked payer policy changes from Kansas Medicaid (KanCare), Michigan Medicaid - MDHHS, and 1 other payer. For billers and coders, staying current on payer-specific coverage criteria, reimbursement rules, and prior-authorization requirements for HCPCS Q0221 is critical to clean claim submission. Each entry below links to the full policy analysis with effective dates and action steps.